Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

Background Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug treatment. The potential role of HIV therapeutic vaccines as part of an HIV cure is under consideration. Our aim was to assess the effi cacy , safety, and immunogenicity of Vacc-4x, a peptide-based HIV-1 therapeutic vaccine targeting conserved domains on p24 Gag , in adults infected with HIV-1. Participants Four primary immunisations,

[1]  B. Clotet,et al.  A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication , 2013, Science Translational Medicine.

[2]  I. Baksaas,et al.  Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years , 2012, Scandinavian journal of infectious diseases.

[3]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[4]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[5]  P. Eilers,et al.  A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. , 2012, Clinical immunology.

[6]  J. Lisziewicz,et al.  Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. , 2011, Vaccine.

[7]  Todd M. Allen,et al.  Coordinate linkage of HIV evolution reveals regions of immunological vulnerability , 2011, Proceedings of the National Academy of Sciences.

[8]  Jon Cohen.  The emerging race to cure HIV infections. , 2011, Science.

[9]  M. Carrington,et al.  Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. , 2011, The Journal of infectious diseases.

[10]  J. Singer,et al.  A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune , 2011, AIDS.

[11]  F. Ssali,et al.  Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. , 2011, Vaccine.

[12]  T. Ø. Jonassen,et al.  Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides , 2010, AIDS.

[13]  R. Schooley,et al.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. , 2010, The Journal of infectious diseases.

[14]  E. Rosenberg,et al.  Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection , 2010, PLoS ONE.

[15]  G. Pantaleo,et al.  Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7Rα (CD127) and Perforin Expression , 2010, Journal of Virology.

[16]  T. Flynn,et al.  A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. , 2009, Vaccine.

[17]  Annapaola Callegaro,et al.  CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. , 2009, AIDS.

[18]  B. Walker,et al.  Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) , 2008, AIDS.

[19]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[20]  Q. Sattentau,et al.  EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. , 2008, Vaccine.

[21]  A. Kelleher,et al.  Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy , 2007, Human vaccines.

[22]  C. Rouzioux,et al.  Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. , 2007, AIDS research and human retroviruses.

[23]  J. Lawrence,et al.  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.

[24]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[25]  V. Johnson,et al.  Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. , 2006, The Journal of infectious diseases.

[26]  Tetsuya Nakamura,et al.  Peptide‐loaded dendritic‐cell vaccination followed by treatment interruption for chronic HIV‐1 infection: A phase 1 trial , 2006, Journal of medical virology.

[27]  B. Autran,et al.  Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. , 2005, The Journal of infectious diseases.

[28]  J. Nyhus,et al.  Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. , 2005, Vaccine.

[29]  F. Wit,et al.  Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study , 2005, AIDS.

[30]  T. Harrer,et al.  Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 Nef-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption , 2005, Antiviral therapy.

[31]  J. Nyhus,et al.  HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x) , 2004, AIDS.

[32]  G. M. Ortiz,et al.  Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3 , 2004, Journal of acquired immune deficiency syndromes.

[33]  M. Lederman,et al.  Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. , 2003, The Journal of infectious diseases.

[34]  E. Sandström,et al.  Better preserved immune responses after immunization with rgp 160 in HIV‐1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow‐up , 2003, HIV medicine.

[35]  N. Langeland,et al.  Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. , 2002, AIDS research and human retroviruses.

[36]  J. Angel,et al.  Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression , 2000 .

[37]  Franck,et al.  Prevalence and Prognostic Significance of ECG Abnormalities in HIV-infected Patients: Results from the Strategies for Management of Antiretroviral Therapy (SMART) Study , 2011 .

[38]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.